Off-label use of tocilizumab in patients with SARS-CoV-2 infection.
作者信息
Di Giambenedetto Simona, Ciccullo Arturo, Borghetti Alberto, Gambassi Giovanni, Landi Francesco, Visconti Elena, Zileri Dal Verme Lorenzo, Bernabei Roberto, Tamburrini Enrica, Cauda Roberto, Gasbarrini Antonio
机构信息
UOC Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy.
Dipartimento di Sicurezza e Bioetica Sezione Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, Italy.
出版信息
J Med Virol. 2020 Oct;92(10):1787-1788. doi: 10.1002/jmv.25897. Epub 2020 Jun 29.
Abstract
摘要
相似文献
1
Off-label use of tocilizumab in patients with SARS-CoV-2 infection.托珠单抗在新型冠状病毒肺炎患者中的超说明书用药
J Med Virol. 2020 Oct;92(10):1787-1788. doi: 10.1002/jmv.25897. Epub 2020 Jun 29.
2
Rapid analysis of local data to inform off-label tocilizumab use early in the COVID-19 pandemic.快速分析当地数据，以便在 COVID-19 大流行早期为托珠单抗的超适应证使用提供信息。
Healthc (Amst). 2021 Dec;9(4):100581. doi: 10.1016/j.hjdsi.2021.100581. Epub 2021 Sep 9.
3
Use of subcutaneous tocilizumab in patients with COVID-19 pneumonia.皮下注射托珠单抗在新冠肺炎肺炎患者中的应用。
J Med Virol. 2021 Jan;93(1):32-34. doi: 10.1002/jmv.26016. Epub 2020 Sep 30.
4
Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial.托珠单抗治疗 COVID-19 的疗效：一项非对照、前瞻性临床试验。
Int Immunopharmacol. 2020 Nov;88:106869. doi: 10.1016/j.intimp.2020.106869. Epub 2020 Aug 4.
5
Lack of tocilizumab effect on mortality in COVID19 patients.托珠单抗对 COVID-19 患者死亡率无影响。
Sci Rep. 2020 Oct 13;10(1):17100. doi: 10.1038/s41598-020-74328-x.
6
Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.抗白细胞介素药物治疗重症 COVID-19 患者（COV-AID）：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):468. doi: 10.1186/s13063-020-04453-5.
7
Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19.一项关于托珠单抗在重症 COVID-19 患者中的超适应证使用的前瞻性开放、单臂多中心研究。
Clin Exp Rheumatol. 2020 May-Jun;38(3):529-532. Epub 2020 May 1.
8
Acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab.接受托珠单抗治疗的COVID-19患者的急性高甘油三酯血症
J Med Virol. 2020 Oct;92(10):1791-1792. doi: 10.1002/jmv.25907. Epub 2020 Jun 3.
9
Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.托珠单抗治疗细胞因子风暴综合征的 SARS-CoV-2 患者：一项叙述性综述。
Rev Recent Clin Trials. 2021;16(2):138-145. doi: 10.2174/1574887115666200917110954.
10
A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.一项旨在评估托珠单抗治疗重症 COVID-19 肺炎患者的疗效和安全性的前瞻性、随机、双盲、安慰剂对照试验（TOC-COVID）：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):470. doi: 10.1186/s13063-020-04447-3.
引用本文的文献
1
Therapeutic Impact of Tocilizumab in the Setting of Severe COVID-19; an Updated and Comprehensive Review on Current Evidence.托珠单抗在重症新型冠状病毒肺炎中的治疗作用；对当前证据的最新综合综述
Arch Acad Emerg Med. 2024 May 9;12(1):e47. doi: 10.22037/aaem.v12i1.2217. eCollection 2024.
2
The Ethical Obligation for Research During Public Health Emergencies: Insights From the COVID-19 Pandemic.突发公共卫生事件中的研究伦理义务：COVID-19 大流行带来的启示。
Med Health Care Philos. 2024 Mar;27(1):49-70. doi: 10.1007/s11019-023-10184-6. Epub 2023 Dec 28.
3
Hemophagocytic Syndrome and COVID-19: A Comprehensive Review.噬血细胞综合征与新型冠状病毒肺炎：综述
Cureus. 2023 Mar 14;15(3):e36140. doi: 10.7759/cureus.36140. eCollection 2023 Mar.
4
A Review of Potential Therapeutic Strategies for COVID-19.《COVID-19 的潜在治疗策略综述》
Viruses. 2022 Oct 25;14(11):2346. doi: 10.3390/v14112346.
5
Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine.针对 2019 年冠状病毒病（COVID-19）的靶向治疗：从细胞和基因治疗到免疫治疗和疫苗的启示。
Int Immunopharmacol. 2022 Oct;111:109161. doi: 10.1016/j.intimp.2022.109161. Epub 2022 Aug 18.
6
Immunomodulatory therapies for COVID-19.用于治疗新冠肺炎的免疫调节疗法。
Front Med (Lausanne). 2022 Aug 3;9:921452. doi: 10.3389/fmed.2022.921452. eCollection 2022.
7
Anti-Rheumatic Drugs May Ameliorate the Clinical Course and Outcome of COVID-19 In Rheumatoid Arthritis Patients.抗风湿药物可能改善类风湿关节炎患者COVID-19的临床病程及结局。
Mediterr J Rheumatol. 2022 Mar 31;33(1):68-74. doi: 10.31138/mjr.33.1.68. eCollection 2022 Mar.
8
Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients.托珠单抗-羟氯喹和托珠单抗-瑞德西韦早期治疗重症 COVID-19 患者的疗效。
J Infect Public Health. 2022 Jan;15(1):116-122. doi: 10.1016/j.jiph.2021.10.024. Epub 2021 Nov 2.
9
COVID-19 infection and liver injury: Clinical features, biomarkers, potential mechanisms, treatment, and management challenges.新型冠状病毒肺炎感染与肝损伤：临床特征、生物标志物、潜在机制、治疗及管理挑战
World J Clin Cases. 2021 Aug 6;9(22):6178-6200. doi: 10.12998/wjcc.v9.i22.6178.
10
Early use of tocilizumab in patients with severe pneumonia secondary to severe acute respiratory syndrome coronavirus 2 infection and poor prognostic criteria: Impact on mortality rate and intensive care unit admission.早期使用托珠单抗治疗严重急性呼吸综合征冠状病毒 2 感染所致严重肺炎且预后不良的患者：对死亡率和重症监护病房入住率的影响。
Medicine (Baltimore). 2021 Jul 23;100(29):e26533. doi: 10.1097/MD.0000000000026533.
本文引用的文献
1
Tocilizumab treatment in COVID-19: A single center experience.托珠单抗治疗 COVID-19：单中心经验。
J Med Virol. 2020 Jul;92(7):814-818. doi: 10.1002/jmv.25801. Epub 2020 Apr 15.
2
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.洛匹那韦-利托那韦治疗成人重症 COVID-19 患者的临床试验。
N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.
3
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19.一项关于氯喹治疗 COVID-19 的疗效和安全性的系统评价。
J Crit Care. 2020 Jun;57:279-283. doi: 10.1016/j.jcrc.2020.03.005. Epub 2020 Mar 10.
4
Understanding of COVID-19 based on current evidence.基于现有证据对 COVID-19 的理解。
J Med Virol. 2020 Jun;92(6):548-551. doi: 10.1002/jmv.25722. Epub 2020 Mar 5.
5
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges.严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）和 2019 年冠状病毒病（COVID-19）：疫情和挑战。
Int J Antimicrob Agents. 2020 Mar;55(3):105924. doi: 10.1016/j.ijantimicag.2020.105924. Epub 2020 Feb 17.
6
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.中国武汉 99 例 2019 年新型冠状病毒肺炎患者的流行病学和临床特征：描述性研究。
Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30.
Zotero 插件